Non-small cell lung cancer (NSCLC) patients may greatly benefit from and live significantly longer if treated with the immunotherapy Keytruda (pembrolizumab) than standard chemotherapy, recent research has indicated. Merck said in a statement that Keytruda has now shown a significant survival benefit compared with chemotherapy for lung cancer patients. Keytruda lung cancer treatment demonstrates well a stand-alone therapy or in combination with chemotherapy.
The Keytruda lung cancer trial compared Keytruda and standard chemo therapy for 1,274 patients with non-small cell lung cancer. Analysis shows Keytruda met the trial’s main objective of increasing patients’ overall survival more than chemo. Improvement in overall survival is the ultimate objective in Keytruda lung cancer treatment trials.
Joe Lyon is an experienced Ohio asbestos lawyer and lung cancer attorney reviewing cancer treatment options for victims of asbestos exposure nationwide. Contact The Lyon Firm following a lung cancer or mesothelioma diagnosis to discuss the best treatment options available.
Keytruda Lung Cancer Treatment for Asbestos Victims
Treatment options for non-small cell lung cancer are based on the stage of the cancer and a person’s overall health and lung function. Keytruda is approved in the U.S. to treat diverse types of advanced cancers, including the following:
- Non-small cell lung cancer
- Hodgkin’s lymphoma
- Colorectal cancer
- Melanoma
- Squamous cell carcinoma
- Adenocarcinoma
Legal Action: Compensation for Asbestos-Related Cancer
Many workers around the country have been exposed to asbestos at the workplace and have suffered from related cancer and diseases. Companies who were aware of asbestos health risks and failed to protect their employees may be found liable for certain workplace injuries like the following:
- Lung Cancer
- Asbestosis
- Mesothelioma
- Colorectal Cancer
- Esophageal Cancer
- Adenocarcinoma
